Press Releases

Saint John's and John Wayne Cancer Institute to validate use of cerebrospinal fluid with the Company's Target Selector™ assay platform in patients with known or suspected brain metastases SAN DIEGO , Feb. 27, 2019 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of

Target Selector™ EGFR assays offer ultra-high sensitivity and require less tumor sample than most commercial assays SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will collaborate with Protean

Partnership enables Biocept's data monetization strategy and enhances Prognos' repository of more than 20 billion laboratory records to predict disease earlier SAN DIEGO , Dec. 18, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to

MLS to market Biocept's proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO and ST. PETERSBURG, Fla. , June 21, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, and MediNcrease Health Plans, LLC

Detection of ALK biomarker expression in circulating tumor cells could provide a new method to identify and monitor patients with ALK+ lung cancer SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers in liquid biopsies

Companies to Evaluate Expression and Mutation in NSCLC Therapeutic Target ALK

Integrated solution incorporates testing protocols and real-time test results to help ensure safer, healthier campuses, healthcare facilities and other venues SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and

Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 status in Breast Cancer Patients San Diego, California: ? Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)

Catalyst Pharmaceuticals to make Biocept's Target Selector™ test available to LEMS patients in Phase III Firdapse® trial to screen for cancer every six months for up to two years, at no cost to patients